JAGUAR HEALTH, INC. Preferred Stock Dividends, Income Statement Impact
JAGUAR HEALTH, INC. (JAGX) reported Preferred Stock Dividends, Income Statement Impact of $8.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-08-19
- JAGUAR HEALTH, INC. preferred stock dividends, income statement impact for the quarter ending 2026-06-30 was $8.00K.
- JAGUAR HEALTH, INC. preferred stock dividends, income statement impact for the quarter ending 2026-03-31 was $6.06M.
- JAGUAR HEALTH, INC. preferred stock dividends, income statement impact for the quarter ending 2025-06-30 was $0.00.
- JAGUAR HEALTH, INC. preferred stock dividends, income statement impact for the quarter ending 2025-03-31 was $0.00.
- JAGUAR HEALTH, INC. preferred stock dividends, income statement impact for fiscal 2025 was $141.00K.
- JAGUAR HEALTH, INC. preferred stock dividends, income statement impact for fiscal 2024 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|
| 2026-06-30 | $8.00K 10-Q · filed 2026-08-19 | $6.07M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $6.06M 10-Q · filed 2026-05-20 | ||
| 2025-12-31 | $141.00K 10-K · filed 2026-04-07 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-19 | $0.00 10-Q · filed 2026-08-19 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-20 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |